GlassScriptPhysician profile
Michelle Ryan
NPI 1144316662
$10,690.26
in general payments reported to CMS, 2019-2025
43 companies · $2,162 in 2025
The $2,162 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,017 · 2022: $2,011 · 2023: $3,198 · 2024: $2,303 · 2025: $2,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,601 · Gift: $59.40 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,601.40 |
| Gift | $59.40 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,987.03 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,395.44 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,239.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,074.77 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $820.36 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $785.83 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $346.18 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $316.63 | 2022 | |
| Idorsia Pharmaceuticals US INC | $295.23 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $212.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.17 | 2021-2025 | Jardiance, Tradjenta |
| Mannkind Corporation | $172.29 | 2023-2025 | Afrezza |
| Abbott Laboratories | $163.30 | 2021-2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $157.19 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $152.85 | 2023-2024 | Rexulti |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $117.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $112.76 | 2021-2025 | |
| Dexcom, INC. | $111.64 | 2022-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $81.87 | 2021-2023 | |
| Astellas Pharma US INC | $80.50 | 2021-2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $74.02 | 2022 | |
| Amgen INC. | $73.61 | 2023-2025 | Evenity, Prolia, Otezla |
| Renalytix Ai, INC. | $70.76 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $65.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $62.88 | 2021-2022 | |
| Axsome Therapeutics, INC. | $60.21 | 2025 | Auvelity |
| Baxter Healthcare | $52.24 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $50.43 | 2021-2025 | Lagevrio |
| Phathom Pharmaceuticals, INC. | $47.10 | 2024-2025 | Voquezna |
| Optinose US, INC. | $45.24 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $40.10 | 2025 | |
| Eisai INC. | $39.20 | 2021-2022 | |
| Corium, LLC | $20.70 | 2025 | Azstarys |
| Vantive US Healthcare LLC | $20.50 | 2025 | Renal - Pd |
| Urovant Sciences INC | $19.53 | 2022 | |
| Sanofi Pasteur INC. | $18.20 | 2023 | |
| Phadia US INC. | $18.08 | 2025 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.07 | 2025 | Xifaxan |
| Insulet Corporation | $16.44 | 2025 | Omnipod |
| Horizon Therapeutics Plc | $16.09 | 2021 | |
| Kaleo, INC. | $15.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.04 | 2022 | |
| Currax Pharmaceuticals LLC | $13.25 | 2023 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.